Clinical Impact of Mass Spectrometry* in the Management of Monoclonal Gammopathies


Wednesday, July 26
Time: 12:45 p.m. - 1:45 p.m.
Location: Exhibit Hall Theatre 1
Supported by Binding Site


Part 1: New technologies for M-protein identification and quantification

Part 2: Revolutionizing Clinical Diagnostics: my experience with mass spectrometry

*This workshop discusses research on potential applications of mass spectrometry in the field of monoclonal gammopathies. The Binding Site, part of Thermo Fisher Scientific is working in this arena although at this time does not have a regulatory cleared product for sale or commercially available for this purpose and future commercial availability cannot be guaranteed.


After attending this session, participants will be able to:

  • Review the current practices of monoclonal gammopathy (MG) management, including the challenges and opportunities.
  • Learn about blood measurement for M-proteins, and their sensitivity and specificity.
  • Hear from a user’s experience of mass spectrometry*, in clinical practice.
  • Understand how mass spectrometry* could address an unmet clinical need in MGs.


Prof. Angela Dispenzieri, MD
Professor of Medicine, Mayo Clinic, Rochester, USA

Jamie Ashby, PhD
Technical development lead, The Binding Site, part of Thermo Fisher Scientific, Birmingham, UK

Prof. Andrew Neish, MD
Professor of Pathology, Emory University, Atlanta, USA